A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Chronic lymphocytic leukemia is a type of blood cancer that affects people around the

world. People with CLL suffer from enlarged lymph nodes, spleen, or liver, or have

symptoms like night sweats, weight loss and fever. They have shorter life expectancy

compared to healthy people. There is an urgent need for new treatment to prolong life and

control disease-related symptoms.

In this study, participants with relapsed/refractory (R/R) CLL who were previously

exposed to a BTKi and a BCL2i will receive tacabrutideg or the investigator's choice of

idelalisib plus rituximab (for CLL only) or bendamustine plus rituximab or venetoclax

plus rituximab retreatment. The main purpose of this study is to compare the length of

time that participants live without their CLL or SLL worsening between those participants

who receive tacabrutideg versus the investigator's choice of treatment (idelalisib plus

rituximab or bendamustine plus rituximab, or venetoclax plus rituximab).

Approximately 250 participants will be included in this study around the world.

Participants will be randomly allocated to receive either tacabrutideg or the

investigator's choice of treatment.

"Our company, previously known as BeiGene, is now officially BeOne Medicines. Because

some of our older studies were sponsored under the name BeiGene, you may see both names

used for this study on this website."